Spinal zap device could ease chemo nerve pain

NCT ID NCT07304401

Recruiting now Symptom relief Sponsor: Rijnstate Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a closed-loop spinal cord stimulator can reduce pain and improve quality of life in people with nerve damage from chemotherapy. The device automatically adjusts stimulation based on nerve responses. Twenty adults with persistent pain will be followed for a year after implantation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: closed-loop spinal cord stimulation (CL-SCS) device
What this could lead to: If it works, this could offer a new way to manage chronic nerve pain from chemotherapy without relying solely on medication.
What could go wrong: This is a small observational study with only 20 participants, so results may not apply to everyone. The device requires surgery and carries risks like infection or lead migration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy neuralgia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY (CIPN) NEUROPATHIC PAIN

Contacts and locations

Locations

ASZ
RECRUITING

Zwijndrecht, Netherlands
Bravis Hospital
RECRUITING

Roosendaal, Netherlands
ETZ
RECRUITING

Tilburg, Netherlands
Rijnstate Hospital
RECRUITING

Arnhem, 6815 AD, Netherlands
Sint Antonius Ziekenhuis
RECRUITING

Nieuwegein, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.